Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

In addition to Organon’s current products, the company invests in ... Medicaid and health care reform, pharmaceutical reimbursement and pricing in general; an inability to fully execute on ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Global pharmaceutical manufacturing ... biosimilars, and over 60 products and therapies for women's health. Organon & Co. (NYSE:OGN) has a strong range of products and is always trying to make ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Another key investment thesis I highlight is Organon's extremely high dividend yield of 7.32%, which is more than 2 times greater than that of Big Pharma players. I also believe that any ...

Organon and Shanghai Henlius Biotech have announced that the European Medicines Agency (EMA) has validated a marketing authorisation application for HLX11, a biosimilar candidate referencing Roche’s ...

Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas.